Obesity Treatment Landscape - The industry recognizes obesity as a disease influenced by genetics and environmental factors [9][10] - New medications like GLP-1 receptor agonists (semaglutide, tirzepatide) signal the brain to reduce hunger, helping individuals maintain a lower weight set point [12] - Despite the availability of new medications, over 60% of individuals discontinue use within one year, often due to costs exceeding $500 per month and lack of insurance coverage [15] - Disparities in access to obesity care medications exist, with affluent individuals having greater access compared to vulnerable populations [17] - The industry is concerned about counterfeit drugs and unregulated compounding pharmacies offering cheaper versions of obesity care medications [18] - Obesity stigma persists, with individuals often being told to lose weight "the natural way," unlike other chronic diseases [18][19] - The industry believes that the current moment is a "miracle moment" for obesity care, with medications preventing diabetes and heart attacks [20] - New medications are being developed that could provide even more options and benefits to patients [21] Call to Action - The industry needs to fund obesity research to better understand treatment and prevention [21][22] - The industry needs to improve access to obesity care, including lifestyle interventions, medications, and surgery, for all patients [22] - The industry needs to end obesity stigma and treat obesity as a chronic disease [23]